In re Patent Application of

LEVINE et al.

Atty. Ref.: JSP-4110-42

Serial No. 10/536,800

TC/A.U.: 1655

Filed: May 27, 2005

Examiner: C. Chen

For: SOLID MUCOADHESIVE COMPOSITION

August 29, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

08/30/2007 HAHAED1 00000040 10536800 01 FC:1806

180.00 Op

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby

Sir:

directed to the reference(s) listed on the attached PTO/SB/08a. One copy of the reference(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
This Information Disclosure Statement ("IDS") is being filed within three (3) months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
 ☑ This application was filed after June 30, 2003 so that copies of U.S. Patent Publications are not required and are not attached. ☑ This IDS is being filed more than three (3) months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. ☐ a. I hereby certify that each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this IDS. 37 C.F.R. 1.97(e)(1). ☐ b. I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign paten office in a counterpart foreign application, and, to the knowledge of the person signing the
statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c)

more than three months prior to the filing of the information disclosure statement. 37 C.F.R. 1.97(e)(2). C. Attached is our check in the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Dep Acct No. 14-1140 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.
This IDS is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 to cover payment of the petition fee under 37 C.F.R. 1.17(I)(1). Please credit or debit Deposit Account No. 14-1140 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached. a. I hereby certify that each item of information contained in this IDS was first cited in the attached communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this IDS. 37 C.F.R. 1.97(e)(1). b. I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign paten office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. 1.97(e)(2).
Relevance of the non-English language reference(s) is discussed in the present specification.
☐ The references were cited in co-pending U.S. application Serial No. 10/478,718.
A concise explanation of the relevance of the non-English language reference(s) appears in the Appendix hereto.
The Examiner's attention is directed to co-pending U.S. Patent Application No., filed, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
Copies of the references were cited by or submitted to the Office in parent Application No, filed and are being resubmitted herein for the Examiner's consideration. Form PTO 1449 is attached with copies of the

LEVINE et al. Serial No. 10/536,800

aforementioned references.

Please charge any fee associated with the filling of this paper to our Deposit Account No. 14-1140.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By

Joseph S. Presta Reg. No. 35,329

JSP:mg 901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORMATION DISCLOSURE	ATTY, DOCKET NO.	SERIAL NO.	
CITATION OF E	4110-42	10/536,800	
	APPLICANT		
AUG 2 9 2007 6	LEVINE et al.		
(Use several sheet) if necessary)	FILING DATE	GROUP	
MORNIA	May 27, 2005	1655	

•	MA PROPRIETO	May	27, 2005	655			
			I.S. PATENT DOCUMENTS				
EXAMINER							DATE
INITIAL	DOCUMENT NUMBER 2004/0151789	8/2004	NAME LEVINE et al.	CLASS	SUBCLASS	<u>IF APPRO</u>	OPRIAT
	5,723,143	3/1998	JACQUES et al.				
	4,740,365	4/1988	YUKIMATSU et al.				
	2002/0044964	4/2002	BOLOGNA et al.				·
	6,350,784	2/2002	SQUIRES				
	6,428,819	8/2002	LAVIE et al.	-			
	5,162,037	11/1992	WHITSON-FISCHMAN			 	
	6,039,949	3/2000	PERO				
	0,039,949	3/2000	1 ERO				
		FOR	REIGN PATENT DOCUMENTS			i	
		1 01	CLOW FAICHT BOOOMENTO			TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	98 42188	10/1998	WIPO				
			ncluding Author, Title, Date, Pertine				
			eia, 30 th Ed.", 1993, The Pharmaceutical		, XP0022116	575 (Prep	aration
			blex, Sinotar as listed on XP-002211675) search and the Remaining Critical Issues,		oriodontal D	accerch 1	000
	Vol. 34, pages 331-339.		search and the Kemanning Critical Issues,	Journal of F	eriouoniai Ki	escarcii, i	777,
			WORT"; Hospital Pharmacy, Lippincott	Philadelphia	US. vol. 32	no. 12. 1	1997.
	pages 1621-1628 and 16			, i iiiaaa piia	, 00, 101. 52	,	.,,
			-WIRKUNGEN UND WIRKSUBSTAN	ZEDN"; Zeits	chrift Fuer A	erztliche	
			, pages 111-115, XP000198717.	·			
			AL ACTIVITY OF THE INFUSION (S				
			APRTS OF HYPERICUM PERFORATU				
			JENZA AND HERPES SIMPLEX VIRU	JSES"; Phytot	her Res., vol	. 4, no. 3,	, 1990
	pages 97-100, XP00109		LI EVILLON FUR AR TYPE LINES AROTT	TEVED! 1001	Contra Cin	l 3 <i>I</i> 1 -	_
			I-LEXIKON FUR ARZTE UND APOTH -121 and 87. XP002211676.	IEKER", 1981	, Gustav Fis	ner veria	g,
			OSY PHYTOCHEMISTRY MEDICINA	I DI ANTS"	1000 Lavois	ier Public	china
			and 366-367, XP002211677.	LILANIS,	1999, Lavois	sici i ubii:	smig,
			Sensible Guide to the Use of Herbs and R	elated Remed	ies, Pharmac	eutical P	roducts
			ges 115-117, XP002914645.		,		
			PHARMACOLOGICAL AND CLINIC	AL PROFILI	E OF THE E	EAST AS	SIAN
			SIATICA"; PHYTOMEDICINE: INTER				
			PHARMACOLOGY. GERMANY, OCT	OBER 2000	, VOL. 7, N	D. 5, PA	GES
	427-448, XP0022116				m 11 =		
	, ,	and Evaluation	on of Buccal Adhesive Hydrocortisone A	cetate (HCA)	Tablets", Dr	ug Delive	ery, Vo
	8, pages 161-171.						

	Ceschel et al., "I 8, pages 161-171	gn and Evaluation of Buccal Adhesive Hydrocortisone Acetate (HCA) Tablets", Drug Delivery, Vol
*Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. In		
examiner: Initial if reference considered, whether or not citation is in conformance with MPEP, 609; draw line through citation if not in conformance and not considered. In	Examiner	Date Considered
nis form with next communication to application.		